Recursion Pharmaceuticals Inc. (RXRX) Next Earnings Date & Options-Implied ±6.9% Move

$4.24 -2.53% NASDAQ • Public Delayed / 60s Snapshot

Recursion Pharmaceuticals Inc. (RXRX) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.

ROARABLE D+ • SELL / AVOID Cap $2.53B

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

5-PILLAR SNOWFLAKE RADARRw D · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS TUG-OF-WAR:50% Call Buyers ($2.3M)

50% PutsMax Pain: $4.00

NEXT EST. REPORT: Dec 30, 2026 (~59 DAYS)

Options-Implied Post-Earnings ±6.9% Bell Curve

±$0.29 Expected Swing

TRADER CROWD SENTIMENT POLL

Will RXRX Beat & Rip or Miss Next Quarter?

Trailing EPS: $-1.08 • YoY Revenue Growth: 26.9%

45% Bullish Beat55% Bearish Miss

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$74.7M	-$644.8M	-$378.3M	5%
FY 2024	2024-12-31	$58.8M	-$463.7M	-$372.9M	23.1%
FY 2023	2023-12-31	$44.6M	-$328.1M	-$289.8M	44%

🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk

Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring RXRX)

✓Live walkthrough of RXRX's RQD Radar, SEC cash-conversion gap & downside levels
✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
✓Includes instant 24/7 email alert whenever any of your stocks flip to Red

RQD INSIDER CLUB UPGRADE$49/YEAR

Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?

🤖 Try AI Indicator Builder ($49/yr VIP) →$100K Arena

RXRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +16.47%▲ ASCENDING CHANNEL

2026-10-30O $4.05H $4.16L $3.79C $4.03VOL 24.39M

RES: $5.43SUP: $3.56SMA50: $3.74SMA200: $3.53

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RXRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RXRX Butterfly Map → + Track RXRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

24.7%/yr Implied 5Y Growth

vs. +26.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RXRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RXRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RXRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

RXRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is RXRX's next earnings date?

Based on SEC filing cadence, Recursion Pharmaceuticals Inc. (RXRX)'s next quarterly earnings window is estimated around Dec 30, 2026.

How much is RXRX stock expected to move on earnings?

Options markets currently imply a ±6.9% post-earnings move for RXRX, projecting a trading range between $3.95 and $4.53.

Direct Sub-Reports: RXRX RQD Cockpit RXRX 12M Forecast RXRX Earnings & Move RXRX Dividends & DRIP RXRX Insiders & 13F RXRX Whale Options RXRX Profit Sankey RXRX News & Why